Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A
Yap, Timothy A, Schram, Alison, Lee, Elizabeth K, Simpkins, Fiona, Weiss, Mia C, LoRusso, Patricia, Højgaard, Martin, Carneiro, Benedito A, Moy, Ryan H, Garrido-Laguna, Ignacio, Koehler, Maria, Unger, Thaddeus J, Bacque, Emeline, Aguado-Fraile, Elia, Sethuraman, Sunantha, Dhake, Snehal, Liu, Yajun, Fretland, Adrian J, Sun, Xizi, Xu, Yi, Hawkey, Nathan, Truong, Jen, Lheureux, Stephanie
Published in Molecular cancer therapeutics (01.12.2023)
Published in Molecular cancer therapeutics (01.12.2023)
Get full text
Journal Article